AstraZeneca agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of AstraZeneca’s efforts to grow its cell therapies business.
Wall Street Journal
AstraZeneca agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of AstraZeneca’s efforts to grow its cell therapies business.